Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 2/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.31 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17240285 | 0.82 | SLC7A5 (0.41) | DGAT1CA1CA2CA7NOS1 | |
| SCHEMBL10608008 | 0.82 | SLC7A5 (0.41) | DGAT1CA1CA2CA7NOS1 | |
| SCHEMBL10606693 | 0.80 | NOS1 (0.33) | DGAT1CA1CA2CA7NOS1 | |
| SCHEMBL1089194 | 0.80 | DGAT1 (0.36) | DGAT1CA1CA2CA7CYP2D6 | |
| SCHEMBL4209325 | 0.77 | CA1 (0.32) | DGAT1CA1CA2CA7NOS1 | |
| SCHEMBL10609673 | 0.77 | SLC7A5 (0.47) | CA1CA2CA7NOS1NOS3 | |
| SCHEMBL30053525 | 0.77 | SLC7A5 (0.47) | CA1CA2CA7NOS1NOS3 | |
| SCHEMBL11387554 | 0.76 | DGAT1 (0.33) | DGAT1CA1CA2CA7CYP2D6 | |
| SCHEMBL8868010 | 0.76 | DGAT1 (0.33) | DGAT1CA1CA2CA7CYP2D6 | |
| SCHEMBL10607365 | 0.76 | SLC7A5 (0.33) | DGAT1CA1CA2CA7NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240415973-A1 | USES OF HYALURONAN CONJUGATES | AIHOL CORPORATION (US) | 2024-12-19 | — | — | US | disclosed |
| CN-118791541-B | ROS-responsive decitabine prodrug compound and preparation method and application thereof | 中国药科大学 | 2024-11-29 | — | — | CN | disclosed |
| US-12128108-B2 | Hyaluronan conjugates and uses thereof | AIHOL CORPORATION (US) | 2024-10-29 | — | — | US | disclosed |
| CN-118791541-A | ROS-responsive decitabine prodrug compound and preparation method and application thereof | 中国药科大学 | 2024-10-18 | — | — | CN | disclosed |
| CN-113660933-B | Hyaluronic acid complexes and uses thereof | 爱禾公司 | 2023-12-01 | — | — | CN | disclosed |
| US-20230080473-A1 | HYALURONAN CONJUGATES AND USES THEREOF | AIHOL CORPORATION (US) | 2023-03-16 | — | — | US | disclosed |
| US-11524079-B2 | Hyaluronan conjugates and uses thereof | AIHOL CORPORATION (US) | 2022-12-13 | — | — | US | disclosed |
| CN-114716662-A | Acrylic acid and derivative functionalized water-soluble polymer thereof and application thereof | 北京键凯科技股份有限公司 | 2022-07-08 | — | — | CN | disclosed |
| US-11337951-B2 | Biologically active cannabidiol analogs | UNIVERSITY OF MISSISSIPPI (US) | 2022-05-24 | — | — | US | disclosed |
| US-11299513-B2 | Cyclative release of peptidic compounds | CIRCLE PHARMA, INC. (US) | 2022-04-12 | — | — | US | disclosed |
| EP-3976019-A1 | HYALURONAN CONJUGATES AND USES THEREOF | Aihol Corporation (US) | 2022-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11299513-B2 | Cyclative release of peptidic compounds | VIP, FURIN, PTMS | DGAT1 4306/4885CA1 347/4885CA2 1605/4885 |
| US-11337951-B2 | Biologically active cannabidiol analogs | CNR2, CNR1, OPRM1 | DGAT1 715/4885CA1 2436/4885CA2 1719/4885 |
| US-20230080473-A1 | HYALURONAN CONJUGATES AND USES THEREOF | CD44, SHBG, HTT | DGAT1 2222/4885CA1 453/4885CA2 3969/4885 |
| US-20240415973-A1 | USES OF HYALURONAN CONJUGATES | CD44, SHBG, HTT | DGAT1 1985/4885CA1 329/4885CA2 3769/4885 |
| US-11524079-B2 | Hyaluronan conjugates and uses thereof | CD44, SHBG, HTT | DGAT1 2205/4885CA1 711/4885CA2 4158/4885 |
| US-12128108-B2 | Hyaluronan conjugates and uses thereof | CD44, SHBG, HTT | DGAT1 2222/4885CA1 453/4885CA2 3969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.